Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ENZN $1.42 0.2100 +17.36%
ONCY $0.63 0.0900 +16.67%
DVAX $25.51 1.9400 +8.23%
AGEN $9.17 0.5600 +6.50%
VSTM $7.50 0.4400 +6.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BPTH $1.10 -0.1000 -8.33%
GTXI $1.45 -0.1200 -7.64%
OHRP $2.30 -0.1800 -7.26%
PVCT $0.53 -0.0300 -5.36%
CBMG $35.36 -1.8400 -4.95%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Amgen's Vectibix Boosts Survival in Colorectal Cancer Patients

(PharmaTimes [UK]) June 19, 2015 - Amgen’s biologic Vectibix has hit the primary goal of a Phase III trial boosting overall survival in patients with metastatic colorectal cancer who have failed to respond to chemotherapy compared to best supportive care.
read article 

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients

(MarketWatch) June 19, 2015 - Bristol-Myers Squibb Company today announced that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status.
read article 

Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care

(MarketWatch) June 18, 2015 - Amgen today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
read article 

NICE Seeks More Information on Treatment For Adults With Leukaemia

(NICE) June 18, 2015 - The National Institute for Health and Care Excellence (NICE) has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig, Gilead Sciences) for adults with chronic lymphocytic leukaemia.
read press release 

Drug Accelerated Growth in Children With Dwarfism, Pharmaceutical Firm Says

(New York Times) June 17, 2015 - An experimental drug, vying to become the first approved treatment for dwarfism, improved growth in children by a significant amount in a preliminary study, the drug’s developer, BioMarin Pharmaceutical, said on Wednesday.
read article 

EU Approval For New Sanofi, Merck Vaccine

(Pharmafile [UK]) June 18, 2015 - Sanofi and Merck are looking forward to a successor to their blockbuster Gardasil now that the European Commission has granted marketing authorisation for a new vaccine in Gardasil 9.
read article 

FDA Unveils New Website Improvements to Help Industry Keep Track of REMS

(RAPS) June 17, 2015 - The US Food and Drug Administration (FDA) is making it easier to find information about the controls that police use of some of the most dangerous drugs approved for use in the US.
read article 

The Government Has No Backup Plan If Court Rules Against Obamacare

(Bloomberg) June 17, 2015 - Millions of Americans could lose their insurance if the U.S. Supreme Court rules against President Barack Obama on his health-care law.
read article 

Authorities Arrest 243 People in $712 Million Medicare fraud

(Reuters) June 18, 2015 - The U.S. Department of Justice said on Thursday that 243 people have been arrested across the country, charged with submitting fake billing for Medicare, a government healthcare program, that totaled $712 million.
read article 

Tyrogenex and Xcovery Open New Office in Needham

(MarketWatch) June 18, 2015 - Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, and Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced the opening of a new office in Needham, Mass., in partnership with the Massachusetts Life Sciences Center (MLSC) during the Biotechnology Industry Organization’s BIO International convention.
read article 

Mayo Clinic and TGen Help Launch Clinical Trials to Combat Advanced Skin Cancer

(Mayo Clinic) June 18, 2015 - Mayo Clinic and the Translational Genomics Research Institute (TGen) are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer.
read press release 

Cure Forward Creates First ‘Patient Activation’ Platform Launching in September 2015

(StreetInsider) June 18, 2015 - Cure Forward, an online patient activation platform, today announced the creation of a new offering for patients to understand and use their personal molecular data.
read article 

Biotech’s Coming Cancer Cure

(MIT Technology Review) June 18, 2015 - Supercharge your immune cells to defeat cancer? Juno Therapeutics believes its treatments can do exactly that.
read article 

Updated Results From Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)

(Yahoo! Finance) June 18, 2015 - TG Therapeutics, Inc. today announced updated clinical results from its Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, the oral BTK inhibitor.
read article 

US Oncology Research and Cure Forward to Advance Clinical Research and Precision Medicine Together

(The US Oncology Network) June 18, 2015 - US Oncology Research, one of the nation's largest networks of integrated, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, announced today a new collaboration with Cure Forward, a patient activation company.
read corporate press release 

ASCO Plans to Release Conceptual Value Framework to Assess the Value of New Cancer Treatment Options

(ASCO in Action) June 17, 2015 - ASCO will release, for public comment, a conceptual framework for assessing the value of new cancer treatment options as compared with older treatments based on clinical benefits, side effects, and costs.
read article 

Gene Therapy Pioneer John Zaia, M.D., Named Director of the Center for Gene Therapy

(City of Hope) June 17, 2015 — Gene therapy pioneer John A. Zaia, M.D., has been named director of the Center for Gene Therapy within City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute.
read press release 

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

(4-traders) June 18, 2015 - Daiichi Sankyo Company, Limited today announced the initiation of Hokusai-VTE Cancer, a multinational study, which will investigate the efficacy and safety of edoxaban, marketed in the U.S. as SAVAYSA®, an oral, once-daily selective factor Xa inhibitor, versus dalteparin for the treatment of VTE associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term treatment with a low molecular weight heparin (LMWH) is intended.
read article 

New Clinical Trial Harnesses the Power of the Immune System to Fight Brain Cancers

(City of Hope) June 18, 2015 — City of Hope initiates human study using CAR-T cell immunotherapy to target glioblastomas.
read press release 

Tests to Gauge Genetic Risks for Prostate Cancer Now Are Feasible

(UCSF) June 17, 2015 - Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.
read article 

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

(UC San Diego Health System) June 17, 2015 - Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend.
read press release 

Genomic Discovery of Skin Cancer Subtypes Provides Potential ‘Signpost’ For Drug Targets

(MD Anderson) June 18, 2015 - Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes. A finding that could prove valuable in the ever-increasing pursuit of personalized medicine.
read press release 

Endometrial Cancer Responds to Novel mTOR Inhibitor

(MedPage Today) June 17, 2015 - The mTOR inhibitor ridaforolimus, when given to patients with recurrent or metastatic endometrial cancer for whom standard therapy has failed, appears to be safe and effective in prolonging progression-free survival (PFS), a randomized, phase II trial found.
read article (free registration required) 

Battle of PI3K Inhibitors for Lymphocytic Leukemia Heats Up

(MedPage Today) June 17, 2015 - Three drugs produce high response rates for CLL. Is one of them safer?
read article (free registration required) 

No Chemo Good for High-Risk Acute Promyelocytic Leukemia, Too

(Medscape Medical News) June 17, 2015 - In terms of outcomes for high-risk patients, the overall survival across both groups was 86%, and 77% for high-risk patients over the age of 60.
read article (free registration required)